• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Leap Therapeutics Inc.

    11/3/25 8:44:48 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LPTX alert in real time by email
    DEFA14A 1 tm2528966d3_defa14a.htm DEFA14A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.      )
    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
    Check the appropriate box:
    ☐
    Preliminary Proxy Statement
    ​
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ​
    ☐
    Definitive Proxy Statement
    ​
    ☒
    Definitive Additional Materials
    ​
    ☐
    Soliciting Material under §240.14a-12
    ​
    LEAP THERAPEUTICS, INC.
    ​
    (Name of Registrant as Specified In Its Charter)​
     
    ​
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)​
    Payment of Filing Fee (Check all boxes that apply):
    ☒
    No fee required.
    ​
    ☐
    Fee paid previously with preliminary materials.
    ​
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
    ​

    GRAPHIC

    2025 You May Vote Your Proxy When You View The Material On The Internet. You Will Be Asked To Follow The Prompts To Vote Your Shares. LEAP THERAPEUTICS, INC 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS to be held on December 15, 2025 *Stockholders are cordially invited to attend the Virtual Special Meeting and to vote on the Internet or any mobile device. Dear Stockholder, Notice is hereby given that a Special Meeting of Stockholders of Leap Therapeutics, Inc. (the “Company”) will be held in a virtual format on Monday, December 15, 2025 at 11:00 AM ET. If you were a holder of the Company’s common stock as of the close of business on the record date of October 24, 2025, you will be able to attend the Special Meeting, vote your shares electronically and submit your questions during the live webcast of the meeting by visiting https://www.cstproxy.com/leaptx/sm2025 at the date and time of the meeting. Proposals to be considered at the Special Meeting: (1) To consider and act upon a proposal to amend the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Charter”) to increase the number of authorized shares of Company common stock; (2) To consider and act upon a proposal to amend the Charter to effect a reverse stock split; (3) To consider and act upon a proposal to adopt the Company’s 2025 Equity Incentive Plan; (4) To consider and act upon a proposal to approve and permit, for the purpose of complying with the applicable provisions of Nasdaq Listing Rule 5635, the Company’s issuance of greater than 19.99% of common stock on the exercise of certain warrants, which could result in a potential “change of control” under Nasdaq rules; (5) To consider and act upon a proposal to adjourn the Special Meeting to a later date or time to permit the solicitation of additional proxies. The Board of Directors recommends a vote “FOR” Proposals 1, 2, 3, 4 and 5. Your electronic vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed, dated, and returned the proxy card. The Proxy Materials are available for review at: https://www.cstproxy.com/leaptx/sm2025 CONTROL NUMBER LEAP THERAPEUTICS, INC c/o Continental Proxy Services 1 State Street, New York NY 10004 201423 Leap Therapeutics Proxy Notice Rev2 Front Vote Your Proxy on the Internet: https://www.cstproxyvote.com Have your notice available when you access the above website. Follow the prompts to vote your shares. Vote during the Meeting – If you plan to attend the virtual online special meeting, you will need your 12 digit control number to vote electronically during the special meeting. To attend the special meeting, visit: https://www.cstproxy.com/leaptx/sm2025 MOBILE VOTING On your Smartphone/Tablet, open the QR Reader and scan the below image. Once the voting site is displayed, enter your Control Number from the proxy card and vote your shares.

    GRAPHIC

    2025 LEAP THERAPEUTICS, INC. 47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 Important Notice Regarding the Availability of Proxy Materials For the 2025 Special Meeting of Stockholders to be Held On December 15, 2025 The following Proxy Materials are available to you to review at: https://www.cstproxy.com/leaptx/sm2025 - the Company’s Special Meeting Proxy Statement - the Proxy Card - any amendments or supplements to the foregoing materials that are required to be furnished to Stockholders This is not a ballot. You cannot use this notice to vote your shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. If you would like to receive a paper or e-mail copy of these documents, you must request one. There is no charge for such documents to be mailed to you. Please make your request for a copy as instructed below on or before December 5, 2025 to facilitate a timely delivery. You may also request that you receive paper copies of all future proxy materials from the Company. ACCESSING YOUR PROXY MATERIALS ONLINE Have this notice available when you request a paper copy of the proxy materials or to vote your proxy electronically. You must reference your Control number. REQUESTING A PAPER COPY OF THE PROXY MATERIALS By telephone please call 1-888-266-6791, or By logging on to https://www.cstproxy.com/leaptx/sm2025 or By email at: [email protected] Please include the company name and your control number in the subject line. 201423 Leap Therapeutics Proxy Notice Rev2 Back

    Get the next $LPTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LPTX

    DatePrice TargetRatingAnalyst
    1/29/2025Buy → Neutral
    H.C. Wainwright
    1/29/2025$9.00 → $1.25Outperform → Neutral
    Robert W. Baird
    6/28/2024$8.00Buy
    Rodman & Renshaw
    10/4/2021$6.00Buy
    Mizuho
    9/14/2021$3.00 → $4.00Outperform
    Raymond James
    More analyst ratings

    $LPTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leap Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Leap Therapeutics from Buy to Neutral

    1/29/25 7:15:39 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Leap Therapeutics from Outperform to Neutral and set a new price target of $1.25 from $9.00 previously

    1/29/25 7:15:19 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Leap Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Leap Therapeutics with a rating of Buy and set a new price target of $8.00

    6/28/24 8:18:39 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

    Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to continue supporting development of sirexatamab in DKK1-high CRC patients CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and ch

    10/20/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

    CAMBRIDGE, Mass., Oct. 9, 2025 /PRNewswire/ -- Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has closed its previously announced private placement led by Winklevoss Capital raising $58,888,888 in cash to initiate a digital asset treasury strategy. At the closing of the transaction, Leap issued (i) 15,212,311 shares of common stock (the "Shares"), (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 80,768,504 shares of common stock, and (ii) warrants to purchase an additional 71,985,605 shares of common stock at an exercise price of $0.5335 per share (the "War

    10/9/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

    CAMBRIDGE, Mass., Oct. 6, 2025 /PRNewswire/ -- Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888 in cash commitments for a private investment in public equity ("PIPE") offering led by Winklevoss Capital to initiate a digital asset treasury strategy. Leap has entered into a securities purchase agreement for the purchase and sale of (i) 95,849,353 shares of common stock (the "Purchased Shares") or pre-funded warrants in lieu thereof (the "Purchased Pre-Funded Warrants") and (ii) warrants to purchase an additional 71,887,008 shares of common stock at an exercise price of $0.5335 per share (the "P

    10/6/25 9:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Leap Therapeutics Inc.

    DEFA14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

    11/3/25 8:44:48 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Leap Therapeutics Inc.

    DEF 14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

    11/3/25 8:39:52 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Leap Therapeutics Inc.

    PRE 14A - LEAP THERAPEUTICS, INC. (0001509745) (Filer)

    10/24/25 4:58:01 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Scientific Officer Baum Jason

    4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

    7/1/25 4:31:50 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Lawlor Augustine

    4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

    7/1/25 4:30:53 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Manufacturing Officer O'Mahony John Mark

    4 - LEAP THERAPEUTICS, INC. (0001509745) (Issuer)

    7/1/25 4:30:15 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    Financials

    Live finance-specific insights

    View All

    Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025

    Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm Leap to continue supporting development of sirexatamab in DKK1-high CRC patients CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and ch

    10/20/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy

    CAMBRIDGE, Mass., Oct. 6, 2025 /PRNewswire/ -- Leap Therapeutics (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced $58,888,888 in cash commitments for a private investment in public equity ("PIPE") offering led by Winklevoss Capital to initiate a digital asset treasury strategy. Leap has entered into a securities purchase agreement for the purchase and sale of (i) 95,849,353 shares of common stock (the "Purchased Shares") or pre-funded warrants in lieu thereof (the "Purchased Pre-Funded Warrants") and (ii) warrants to purchase an additional 71,887,008 shares of common stock at an exercise price of $0.5335 per share (the "P

    10/6/25 9:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Reports Second Quarter 2025 Financial Results

    CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap Highlights: Board of Directors initiated process of exploring strategic alternatives to maximize shareholder valueStrategic restructuring to prioritize corporate development resulting in a further 75% reduction in workforceReported updated data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC)"This past quarter, we undertook a strategic

    8/14/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    Leadership Updates

    Live Leadership Updates

    View All

    Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

    CAMBRIDGE, Mass., Sept. 6, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the appointment of Richard L. Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers. "We are honored to welcome Dr. Schilsky, who brings a wealth of experience and deep knowledge to bolster Leap's drug development strategy," said Christopher Mirabelli, PhD, Chairman of Leap Therapeutics' Board. "He is a

    9/6/22 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LPTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Leap Therapeutics Inc.

    SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

    11/14/24 6:07:56 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Leap Therapeutics Inc.

    SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

    4/25/24 8:39:23 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Leap Therapeutics Inc.

    SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

    4/19/24 4:31:26 PM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care